David J. Drutz, MD, Chairman of the Board
Dr. Drutz, who was first elected to our board of directors in January 2010 and has served as Chairman of the Board since October 2011, is the President of Pacific Biopharma Associates, a biopharmaceutical consulting company that he founded in January 1999. Between 2008 and 2015, he served as Director (March 2008-December 2015), Chief Executive Officer (December 2011-June 2014), Executive Chairman (June 2014-December 2015) and Chief Medical Officer (January 2012-December 2015) of DARA BioSciences, an oncology supportive care company located in Raleigh, NC, which was acquired by Midatech Pharma in December 2015. Dr. Drutz served previously as Chairman of Tranzyme, Inc. (NASDAQ:TZYM, 2000-2010) acquired by Ocera Therapeutics (NASDAQ:OCRX); Director of MethylGene, Inc. (TSX:MYG, 2000-2010) acquired by Mirati Therapeutics (NASDAQ:MRTX); and Director of Gentris Corporation (2007-2014), acquired by Cancer Genetics (NASDAQ:CGIX). From 1999 to 2008 he was a general partner with Pacific Rim Ventures, a Tokyo-based international venture capital firm. He is a former member of the Science and Industry Advisory Committee (SIAC) of Genome Canada, which advises Genome Canada’s board of directors regarding genomics investments throughout Canada. Dr. Drutz’s management experience includes tenures as VP Biological Sciences and VP Clinical Research at Smith Kline & French Laboratories, VP Clinical Development at Daiichi Pharmaceutical Corporation, and CEO of Inspire Pharmaceuticals (1995-1998) and Sennes Drug Innovations (1994-1995). Earlier in his career, Dr. Drutz was Professor of Medicine and Chief of the Division of Infectious Diseases at the University of Texas Health Science Center, San Antonio, and prior to that appointment was Assistant Professor of Medicine and Chief of the Division of Infectious Diseases at the University of California, San Francisco/San Francisco General Hospital. Dr. Drutz received his M.D. from the University of Louisville School of Medicine and postgraduate training in internal medicine and infectious diseases at Vanderbilt University School of Medicine, serving subsequently as a research medical officer (infectious diseases) in the U.S. Navy with the rank of Lieutenant Commander. He is certified by the American Board of Internal Medicine, a fellow of the American College of Physicians and the Infectious Diseases Society of America, a member of the American Society of Clinical Oncology and the American Society for Clinical Investigation, and the author of more than 200 peer-reviewed articles, book chapters and abstracts for presentation. We believe Dr. Drutz’s experience in biotechnology investment and service as a board member and qualifications as a physician qualify him to serve as a member of our board of directors.
Philippe Pouletty, MD
Dr. Pouletty, a prominent venture capitalist in Europe, was first elected to our board of directors in March 2015 and is currently serving as chair of our compensation committee. Dr. Pouletty is the co-founder and Managing Partner of Truffle Capital, a position he has held since 2001. He is a Biotech and Medtech industry veteran, with a dual experience in the Silicon Valley and in France. Dr. Pouletty is Founder and Chairman of Deinove (Alternext: ALDEI) and Abivax (Euronext: ABVX); Co-founder and Board member of Carbios (Alternext: ALCRB), Carmat (Alternext: ALCAR), Myopowers, Pharnext, Symetis, Theraclion (Alternext: ALTHE), Theradiag (Alternext: ALTER) and Vexim (Alternext: ALVXM), all of which are Truffle Capital portfolio companies; an Independent Board member of Innate Pharma (Euronext: IPH); and a former Board member of Neovacs (Alternext: ALNEV). Dr. Pouletty also founded SangStat, an organ transplantation therapeutics company, in 1988, which went public in 1993 and was sold in 2002 to Genzyme for $600.0 million; and ConjuChem in 1993, which went public on the Toronto Stock Exchange in 2000. He is the former Chairman (2001-2009) and current Honorary Chairman of France Biotech, the French biotech industry association, and former Vice Chairman of Europabio, the European biotech industry association. He conceived the Young Innovative Entreprise Status (JEI), which was implemented in France by President Chirac in 2004. He is the inventor of 29 patents, including the second highest revenue generating life science patent for Stanford University, earning him entry into the prestigious Stanford University Hall of Fame of Inventors in 2012. A former hematology and immunology resident in Parisian hospitals, Dr. Pouletty holds an M.D. from the University of Paris VI and Master’s in immunology and virology from l’Institut Pasteur, was a post-doctoral research fellow (1986-1988) at Stanford University, and the 1999 laureate of the American Liver Foundation. He was also awarded the Chevalier of the Légion d’Honneur. We believe Dr. Pouletty’s experience as a board member in the biotechnology and pharmaceutical industry and qualifications as a physician and a biotechnology investor qualify him to serve as a member of our board of directors.
Philip L. Hodges
Mr. Hodges was first elected to our board of directors in September 2003 and is currently serving as chair of our audit committee. He is Managing Partner of Redmont Capital, a private equity firm located in Birmingham, Alabama, which he joined at its inception in 1997. Redmont Capital is a co-founder of our company. Mr. Hodges’ investment strategy is focused on high growth small businesses within the health care, life science and technology sectors. He currently serves as a director for several of the firm’s portfolio companies. Mr. Hodges holds a Bachelor of Science in Business Administration from the Brock School of Business at Samford University. We believe Mr. Hodges’ experience as a board member, life science investor and co founder qualifies him to serve as a member of our board of directors.
Brigadier General (ret.) Klaus O. Schafer, MD, MPH
Brigadier General (ret.), Klaus Schafer, M.D., MPH, has over 30 years of leadership experience, having held senior positions in government and industry. He was first elected to our board of directors in July 2012. As the Deputy Asst. to the Secretary of Defense for chemical and biological defense, a position he held from April 2004 through June 2005, he oversaw the management of the Department of Defense’s $1.0 billion program for vaccine, therapeutics, medical device and sensor development. He retired from the Air Force as the Assistant Surgeon General with extensive experience managing all aspects of large integrated health care delivery systems. Prior private sector experience includes VP of business development for Compressus Inc., a telemedicine start-up, former CEO and co-founder of TessArae LLC, a start-up biotech genetic testing company. He is currently Chief Medical Officer and VP, business development, Health for CACI International, a publicly traded Fortune 1000 company. We believe Dr. Schafer’s experience in government and as a board member and advisor in the health care biodefense industry, as well as his qualifications as a physician and as a biotechnology investor, qualify him to serve as a member of our board of directors.
Mårten Steen, MD, PhD
Dr. Steen has been a Partner at HealthCap, a private equity firm, since March 2010. He was first elected to our board of directors in March 2015. Prior to HealthCap, Dr. Steen served as Director of Early Stage Licensing at Merck Serono SA, a biopharmaceutical company, from February 2008 until March 2010. Dr. Steen received a B.Sc. in Business Administration and an M.D. and a Ph.D. in Clinical Chemistry from Lund University. He pursued research in the field of protein chemistry and coagulation at Lund University and Novo Nordisk. He serves as a member of the board of directors of Strongbridge Biopharma Plc, Wilson Therapeutics AB and BioClin Therapeutics Inc. He previously served on the boards of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) and FerroKin Biosciences prior to its acquisition by Shire. We believe that Dr. Steen is qualified to serve on our board of directors due to his medical and scientific background as well as his experience in the venture capital industry.
Christine Brennan, PhD
Dr. Brennan was first elected to our board of directors in September 2016. She joined the Novartis Venture Fund in November 2013. Prior to joining Novartis Venture Fund, Dr. Brennan spent 3 years at Vitae Pharmaceuticals as Chief Business Officer responsible for strategy & business development. Prior to Vitae, she spent 5 years at Novartis Institutes for BioMedical Research in Strategic Alliances, most recently as Executive Director and Head of Strategy & Operations. Prior to Novartis, she held positions in business development and marketing at the biopharmaceutical companies, EnVivo Pharmaceuticals (now FORUM Pharmaceuticals), Biovail (now Valeant Pharmaceuticals) and Cogent Neuroscience. In addition, she was Director at Fidelity Biosciences Group (now F-Prime Capital Partners), a venture capital company. She received her Ph.D. in neuroscience from Dartmouth Medical School in 1995 and completed a postdoctoral fellowship at the National Institutes of Health in 1999.
Bill Enright, MBA
President and CEO - See Management Team. We believe Mr. Enright’s service as our Chief Executive Officer and his experience in the biotechnology industry qualifies him to serve as a member of our board of directors.